ESMO 2026 | Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
Bérengère Salomé, PharmD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on current challenges in treating non-muscle invasive bladder cancer (NMIBC), including high recurrence and progression rates despite BCG treatment, and the need for biomarkers to identify patients who will benefit most from BCG. Dr Salomé highlights two preclinical therapeutic strategies to induce adaptive NK cells, including the use of CMV peptides for potential intravesical administration and an NKG2C agonist antibody for systemic therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
